Nymox Pharmaceutical Corporation (NYMX)
-NasdaqCM 5.19 
0.07(1.33%) May 22, 4:00PM EDT
| Prev Close: | 5.26 |
|---|
| Open: | 5.06 |
|---|
| Bid: | 4.18 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 9.67 |
|---|
| Beta: | 0.94 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 5.06 - 5.40 |
|---|
| 52wk Range: | 4.20 - 8.53 |
|---|
| Volume: | 32,823 |
|---|
| Avg Vol (3m): | 82,762 |
|---|
| Market Cap: | 174.79M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.21 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nymox Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, May 15)
- Nymox Reports on Symposium and Panel Discussion on NX-1207 at American Urological Association Annual MeetingGlobeNewswire(Mon, May 6)
- Nymox Announces Completion of Patient Enrollment in Final Pivotal U.S. Phase 3 BPH StudyGlobeNewswire(Fri, May 3)
- Nymox NX-1207 Symposium May 5 in San Diego at Annual Meeting of American Urological Association at San Diego Convention CenterGlobeNewswire(Tue, Apr 30)
- Nymox Announces First Patient Enrollment for NX02-0022 Reinjection Study of NX-1207 for BPHGlobeNewswire(Tue, Apr 23)
- 3 Healthcare Stock Stories for Wednesday Investment Wellnessat Wall St. Cheat Sheet(Wed, Apr 17)
- New Study Supports Favorable Sexual Function Profile for Nymox's NX-1207 for Prostate EnlargementGlobeNewswire(Tue, Apr 16)
- Nymox NX-1207 BPH and Prostate Cancer Symposium at American Urological Association Annual Meeting May 5 in San DiegoGlobeNewswire(Thu, Apr 11)
- Nymox Pharma: Developing A Potential Long-Term Treatment For BPHat Seeking Alpha(Wed, Apr 3)
- Press Release Issued Under the Early Warning System/Sale of Shares of Nymox Pharmaceutical CorporationGlobeNewswire(Tue, Apr 2)
- Nymox's NicAlert(TM) Has Achieved Widespread Acceptance in Tobacco-Related Research StudiesGlobeNewswire(Wed, Mar 27)
- Good News for Nymox's PipelineZacks(Thu, Mar 21)
- NYMOX PHARMACEUTICAL CORP FinancialsEDGAR Online Financials(Wed, Mar 20)
- 4 Healthcare Stock Stories for Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue, Mar 19)
- Nymox Prostate Cancer Trial Receives Positive Interim Safety Review From Independent Data Monitoring CommitteeGlobeNewswire(Tue, Mar 19)
Key Statistics
| Forward P/E (1 yr): | 34.60 |
|---|
| P/S (ttm): | 55.85 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development, and commercialization of drugs and diagnostic products for the aging population in the United States, Canada, Europe, and other countries.
View More